ELADUR(TM) Development Update: DURECT Receives Orphan Drug Designation for Bupivacaine for Post-Herpetic... ( CUPERTINO Calif. June 30 /- DUREC...)

ELADUR(TM) Development Update: DURECT Receives Orphan Drug Designation for Bupivacaine for Post-Herpetic Neuralgia

Date:6/30/2008

CUPERTINO, Calif., June 30 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that the US Food and Drug Administration (FDA) has granted to DURECT orphan drug designation for bupivacaine for relief of persistent pain associated with post-herpetic neuralgia (PHN). Bupivacaine is the active pharmaceutical ingredient in ELADUR(TM), DURECT's investigational transdermal drug patch. If ELADUR is the first bupivacaine product approved for PHN, under the 1983 Orphan Drug Act ELADUR will receive seven years of market exclusivity following the approval of the product by the FDA.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO)

"The receipt of orphan drug status enhances the product opportunity for ELADUR, including providing a more favorable development pathway," stated James E. Brown, DVM, President and CEO of DURECT. "We are continuing to develop ELADUR as a potentially best in class transdermal product for those suffering from PHN."

ELADUR is an investigational transdermal drug patch intended to deliver bupivacaine for up to 3 days from a single application, as compared to a wearing time limited to 12 hours with currently available anesthetic patches (e.g., Lidoderm(R), an FDA-approved lidocaine patch for post-herpetic neuralgia pain management). Bupivacaine, the active agent in ELADUR, is a potent, FDA-approved long-acting local anesthetic used in regional anesthesia for local tissue infiltration, nerve block, and epidural and intrathecal anesthesia. DURECT currently retains full commercial rights to this product candidate.

DURECT has previously announced positive results for ELADUR from a 60 patien
'/>"/>

SOURCE DURECT Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3
Related medicine technology :

1. DURECT Announces Positive ELADUR(TM) Phase IIa Study Results
2. Marketing of Diagnostics and deCODEme(TM), Recent Progress in Drug Development to be Highlighted at deCODE R&D Event
3. Pressure BioSciences, Inc. Announces $850,000 NIH SBIR Phase II Award for the Development of a New PCT-dependent System for Improved Biomarker Discovery, Diagnostics, and Drug Discovery
4. Champions Biotechnology Begins Preclinical Development of Its Lead Oncology Drug Candidate
5. GeneGo is Awarded NCI Grant for Development of Systems Biology Platform for Integrative Data Analysis in Cancer
6. Victory Pharma, Inc. Reports MGX006 Enters Into Pivotal Development Program
7. Lilly and TransPharma Medical Announce Licensing and Development Agreement
8. Sunesis Pharmaceuticals Focuses Resources on Development of Voreloxin (Formerly SNS-595)
9. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
10. Access Pharmaceuticals Presents Favorable Ovarian Cancer Data and Clinical Update on ProLindac(TM) Development at Prestigious International Symposium
11. BiPar Sciences Expands Clinical Development of BSI-201, A Novel PARP Inhibitor, With Phase 2 Trial in Uterine Cancer

Post Your Comments:

(Date:5/22/2013)... Advanced Prenatal Therapeutics (APT), a privately held ... alleviate the high blood pressure and other symptoms associated ... be the first medical device specifically designed to treat ... Every year, preeclampsia affects approximately 300,000 pregnant ... It is characterized by high blood pressure and proteinuria ...

(Date:5/22/2013)... NEW YORK , May 22, 2013 /PRNewswire/ ... is investigating potential claims on behalf of purchasers ... or the "Company") (NasdaqGS: AMAG -News). The investigation ... violated federal securities laws. On May ... 10.73% during intraday trading after the company announced ...

(Date:5/22/2013)... 2013 The Leukemia & Lymphoma Society (LLS) is ... LLC, a joint venture between ImmunGene and Caliber, to ... Phase I clinical trial for a novel fusion protein ... patients with indolent lymphomas who do not respond to ... IGN002, is a new class of biotherapeutics produced by ...

Breaking Medicine Technology:Advanced Prenatal Therapeutics - Using Targeted Apheresis to Treat Preeclampsia 2 Bronstein, Gewirtz & Grossman, LLC Announces Investigation of AMAG Pharmaceuticals, Inc. 2 The Leukemia & Lymphoma Society, Valor Biotherapeutics and ImmunGene Create Partnership to Advance Novel Therapy for Non-Hodgkin Lymphoma Patients 2 The Leukemia & Lymphoma Society, Valor Biotherapeutics and ImmunGene Create Partnership to Advance Novel Therapy for Non-Hodgkin Lymphoma Patients 3 The Leukemia & Lymphoma Society, Valor Biotherapeutics and ImmunGene Create Partnership to Advance Novel Therapy for Non-Hodgkin Lymphoma Patients 4

[0] Advanced Prenatal Therapeutics - Using Targeted Apheresis to Treat Preeclampsia [0] Bronstein, Gewirtz & Grossman, LLC Announces Investigation of AMAG Pharmaceuticals, Inc.[0] The Leukemia & Lymphoma Society, Valor Biotherapeutics and ImmunGene Create Partnership to Advance Novel Therapy for Non-Hodgkin Lymphoma Patients

... 2012 Niagara Thermal Products LLC is pleased to announce ... acquisition brings together two highly regarded names in the ... in the aerospace, defense and electronics markets. ... addition of Kittredge,s industry recognized dip brazing, welding, machining ...

... N.C., Jan. 23, 2012 As the influence of Managed ... that biopharma companies carry out as part of interacting ... device leaders have placed an increased importance on these ... closely intertwined with marketplace success. On average, ...

Cached Medicine Technology:Niagara Thermal Products LLC Announces the Acquisition of J. Kittredge & Sons, Inc. 2 Niagara Thermal Products LLC Announces the Acquisition of J. Kittredge & Sons, Inc. 3 Pharmaceutical Industry Places Newfound Emphasis on Managed Care Organizations 2 Pharmaceutical Industry Places Newfound Emphasis on Managed Care Organizations 3

Niagara Thermal Products LLC Announces the Acquisition of J. Kittredge & Sons, Inc.Pharmaceutical Industry Places Newfound Emphasis on Managed Care Organizations

(Date:5/22/2013)... 2013 The surging growth in specialty ... through marketing claims to compare mattresses often proves a ... a bed blog , offers shoppers faced with this ... their latest article. , Titled “ Mattress Comparison Overview ... guides readers through the basics of innerspring beds as ...

(Date:5/22/2013)... TX (PRWEB) May 22, 2013 ... sustainable practices in the textile industry, today released ... findings demonstrate that organic cotton production dropped 8% ... dramatic than the staggering 37% drop in 2010-11. ... production. , The report, Textile Exchange’s seventh, ...

(Date:5/22/2013)... Dr. Andrew Satlin offers patients with gum disease ... Assisted New Attachment Procedure (LANAP). May is Stroke Awareness Month, ... gum disease and stroke. Periodontal disease is one of the ... is linked to an increased risk for strokes because of ... pockets. , Periodontal disease is essentially an infection of ...

(Date:5/22/2013)... TWITTER: @the_USO & @SesameStreet are proud to ... in the next 6 months! , Today, the ... came together to show their heartfelt thanks to those who currently ... for distribution to our servicemen and women. The group was ... and the USO as well as the success of the ...

(Date:5/22/2013)... CHARLOTTE, (PRWEB) May 22, 2013 The ... fight against muscular dystrophy at the annual Charlotte Muscle ... $300,000 to help Charlotte-area families living with muscle disease. ... this year's event to support MDA families,” said MDA ... heroes who were partnered with a "Buddy" to make ...

Breaking Medicine News(10 mins):Health News:Mattress Comparison Overview Released by The Sleepy Shopper; Compares Top Types and Brands 2 Health News:Organic Cotton Sector Shows Signs of Stabilizing, Demonstrating Strength and Commitment of Producer Groups, According to 2011-12 Textile Exchange Farm & Fiber Report 2 Health News:Organic Cotton Sector Shows Signs of Stabilizing, Demonstrating Strength and Commitment of Producer Groups, According to 2011-12 Textile Exchange Farm & Fiber Report 3 Health News:Organic Cotton Sector Shows Signs of Stabilizing, Demonstrating Strength and Commitment of Producer Groups, According to 2011-12 Textile Exchange Farm & Fiber Report 4 Health News:For Stroke Awareness Month, Dr. Andrew Satlin is Raising Awareness of the Connections Between Gum Disease and Stroke and Offers Encino, CA Laser Gum Surgery for Treatment 2 Health News:The USO and Sesame Street Announce Spring Kick Off of World Tour at Biannual Care Package Service Project Event in DC 2 Health News:The USO and Sesame Street Announce Spring Kick Off of World Tour at Biannual Care Package Service Project Event in DC 3 Health News:The USO and Sesame Street Announce Spring Kick Off of World Tour at Biannual Care Package Service Project Event in DC 4 Health News:The USO and Sesame Street Announce Spring Kick Off of World Tour at Biannual Care Package Service Project Event in DC 5 Health News:Charlotte Muscle Team Event Raises $300,000 in the Fight Against Muscle Disease 2

[0] Mattress Comparison Overview Released by The Sleepy Shopper; Compares Top Types and Brands [0] Organic Cotton Sector Shows Signs of Stabilizing, Demonstrating Strength and Commitment of Producer Groups, According to 2011-12 Textile Exchange Farm & Fiber Report [0] For Stroke Awareness Month, Dr. Andrew Satlin is Raising Awareness of the Connections Between Gum Disease and Stroke and Offers Encino, CA Laser Gum Surgery for Treatment [0] The USO and Sesame Street Announce Spring Kick Off of World Tour at Biannual Care Package Service Project Event in DC [0] Charlotte Muscle Team Event Raises $300,000 in the Fight Against Muscle Disease

... two surveys find , , THURSDAY, May 15 (HealthDay News) -- ... devices aren,t aware of recent recalls and don,t understand the ... they point to a lack of understanding among both doctors ... treat it, said Dr. Bruce Wilkoff, director of cardiac and ...

... minSURG Corporation, a,subsidiary of Orthopedic Development Corporation, ... used to treat chronic facet-oriented back,pain or to ... fuse each of the two facet joints in ... solutions to treat intractable back pain without,precluding other ...

... May 15 Nephros, Inc. (Amex: NEP ),announced today ... Recent Highlights -- Increased product revenues by ... U.S. trial for the OLpur(TM) H2H(TM) ... Joleen C. Turner as VP of Marketing and Business Development ...

... ... as a ,highlighted, poster at American Heart,Association Conference on Arteriosclerosis, Thrombosis and Vascular ... ... Inc. (TSX: PMD; Amex: PME) today announced unaudited financial,results for the first quarter ...

... hospital, they,re twice as likely to be injured, so prevention ... -- Stroke patients have a high risk of falling after ... , The University of Auckland researchers added that prevention programs ... a stroke fall almost twice as often as people who ...

... is,prepared to provide $10 million to support relief efforts ... This,contribution will assist the Red Cross Society of China, ... earthquake struck on,Monday, May 12. According to the latest ... many more are missing or trapped by debris., ...

Heart Device Recipients Often Not Aware of Recalls TruFUSE(R) Minimally Invasive Facet Fusion Procedure Tops 3,000 Spinal Levels Nephros Reports 2008 First Quarter Financial Results PreMD Reports First Quarter Results Stroke Patients at High Risk for Falls The American Red Cross Commits $10 Million to Assist China Earthquake Survivors

... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...

... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...

Medicine Products:

Pertussis smear, DFA Pertussis Antibody, IgM Perphenazine Percodan, Serum or Plasma